FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1881168102> ?p ?o ?g. }

• W1881168102 endingPage "4008" @default.
• W1881168102 startingPage "4008" @default.
• W1881168102 abstract "4008 Background: Adjuvant chemotherapy with gemcitabine (G) has been standard treatment for resected pancreatic cancer (PC). In the GEST study, S-1 (S) had shown non-inferiority to G in overall survival (OS) for unresectable PC. The aim of this phase III study is to investigate non-inferiority of S to G on OS as adjuvant chemotherapy for resected PC. Methods: Patients (pts) after macroscopically curative resection of PC with an ECOG PS of 0-1 and adequate organ functions were randomly assigned to G (1000 mg/m 2 , iv, d1, 8 and 15, q4w, for 6 courses) or S (80/100/120 mg/day based on BSA, po, d1-28, q6w, for 4 courses) with balancing by surgical margins (R), nodal status (N) and institution. Primary endpoint was OS. With 180 pts per arm, the study had 80% power to prove non-inferiority with a margin of hazard ratio (HR) 1.25 on the basis of expected HR 0.87, with 0.05 two-sided alpha. Secondary endpoints were relapse-free survival (RFS), safety, and quality of life (EQ-5D). One interim analysis was planned after 180 deaths. Results: From 4/2007 to 6/2010, 385 pts were enrolled from 33 hospitals in Japan. 378 pts (G/S: 191/187) were included in the full analysis set. Pts characteristics (G/S) were well balanced (PS0: 67%/70%, R0: 86%/88%, N0: 38%/36%). Based on the interim analysis with 205 OS events, IDMC recommended to publish the results. OS at 2-years were 53% for G and 70% for S. HR for S to G was 0.56 (95% CI, 0.42-0.74, p<0.0001 for non-inferiority, p<0.0001 for superiority). On subgroup analysis, HRs for R0/R1, N0/N1 pts were 0.57 (95% CI, 0.42-0.78)/0.53 (0.27-1.05), 0.48 (0.28-0.83)/0.58 (0.41-0.80), respectively. RFS at 2-years were 29% for G and 49% for S. HR of relapse for S to G was 0.56 (95% CI, 0.43-0.71, log-rank p<0.0001). Incidences of grade 3/4 toxicities in G/S were leukopenia 39%/9%, hemoglobin decrease 17%/13%, thrombocytopenia 9%/4%, elevated AST 5%/1%, fatigue 5%/5%, and anorexia 6%/8%. Relative dose intensity of G/S was 84%/97%. EQ-5D QOL score in S was significantly better than that in G (p<0.0001). Conclusions: S-1 adjuvant chemotherapy is shown non-inferior, and furthermore, even superior to GEM. S-1 is considered as the new standard treatment for resected PC pts. Clinical trial information: UMIN000000655." @default.
• W1881168102 created "2016-06-24" @default.
• W1881168102 creator A5004637658 @default.
• W1881168102 creator A5010090426 @default.
• W1881168102 creator A5014204252 @default.
• W1881168102 creator A5015679349 @default.
• W1881168102 creator A5015760456 @default.
• W1881168102 creator A5017656130 @default.
• W1881168102 creator A5019199908 @default.
• W1881168102 creator A5024294999 @default.
• W1881168102 creator A5024304106 @default.
• W1881168102 creator A5030336630 @default.
• W1881168102 creator A5038049005 @default.
• W1881168102 creator A5041145642 @default.
• W1881168102 creator A5053746579 @default.
• W1881168102 creator A5058266344 @default.
• W1881168102 creator A5063761414 @default.
• W1881168102 creator A5077055208 @default.
• W1881168102 creator A5086609499 @default.
• W1881168102 creator A5090750541 @default.
• W1881168102 creator A5090915905 @default.
• W1881168102 creator A5090955736 @default.
• W1881168102 date "2013-05-20" @default.
• W1881168102 modified "2023-10-03" @default.
• W1881168102 title "JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer." @default.
• W1881168102 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.4008" @default.
• W1881168102 hasPublicationYear "2013" @default.
• W1881168102 type Work @default.
• W1881168102 sameAs 1881168102 @default.
• W1881168102 citedByCount "33" @default.
• W1881168102 countsByYear W18811681022013 @default.
• W1881168102 countsByYear W18811681022014 @default.
• W1881168102 countsByYear W18811681022015 @default.
• W1881168102 countsByYear W18811681022016 @default.
• W1881168102 countsByYear W18811681022017 @default.
• W1881168102 countsByYear W18811681022021 @default.
• W1881168102 crossrefType "journal-article" @default.
• W1881168102 hasAuthorship W1881168102A5004637658 @default.
• W1881168102 hasAuthorship W1881168102A5010090426 @default.
• W1881168102 hasAuthorship W1881168102A5014204252 @default.
• W1881168102 hasAuthorship W1881168102A5015679349 @default.
• W1881168102 hasAuthorship W1881168102A5015760456 @default.
• W1881168102 hasAuthorship W1881168102A5017656130 @default.
• W1881168102 hasAuthorship W1881168102A5019199908 @default.
• W1881168102 hasAuthorship W1881168102A5024294999 @default.
• W1881168102 hasAuthorship W1881168102A5024304106 @default.
• W1881168102 hasAuthorship W1881168102A5030336630 @default.
• W1881168102 hasAuthorship W1881168102A5038049005 @default.
• W1881168102 hasAuthorship W1881168102A5041145642 @default.
• W1881168102 hasAuthorship W1881168102A5053746579 @default.
• W1881168102 hasAuthorship W1881168102A5058266344 @default.
• W1881168102 hasAuthorship W1881168102A5063761414 @default.
• W1881168102 hasAuthorship W1881168102A5077055208 @default.
• W1881168102 hasAuthorship W1881168102A5086609499 @default.
• W1881168102 hasAuthorship W1881168102A5090750541 @default.
• W1881168102 hasAuthorship W1881168102A5090915905 @default.
• W1881168102 hasAuthorship W1881168102A5090955736 @default.
• W1881168102 hasConcept C121608353 @default.
• W1881168102 hasConcept C126322002 @default.
• W1881168102 hasConcept C141071460 @default.
• W1881168102 hasConcept C143998085 @default.
• W1881168102 hasConcept C203092338 @default.
• W1881168102 hasConcept C207103383 @default.
• W1881168102 hasConcept C2776694085 @default.
• W1881168102 hasConcept C2780210213 @default.
• W1881168102 hasConcept C2780258809 @default.
• W1881168102 hasConcept C44249647 @default.
• W1881168102 hasConcept C535046627 @default.
• W1881168102 hasConcept C61943457 @default.
• W1881168102 hasConcept C71924100 @default.
• W1881168102 hasConceptScore W1881168102C121608353 @default.
• W1881168102 hasConceptScore W1881168102C126322002 @default.
• W1881168102 hasConceptScore W1881168102C141071460 @default.
• W1881168102 hasConceptScore W1881168102C143998085 @default.
• W1881168102 hasConceptScore W1881168102C203092338 @default.
• W1881168102 hasConceptScore W1881168102C207103383 @default.
• W1881168102 hasConceptScore W1881168102C2776694085 @default.
• W1881168102 hasConceptScore W1881168102C2780210213 @default.
• W1881168102 hasConceptScore W1881168102C2780258809 @default.
• W1881168102 hasConceptScore W1881168102C44249647 @default.
• W1881168102 hasConceptScore W1881168102C535046627 @default.
• W1881168102 hasConceptScore W1881168102C61943457 @default.
• W1881168102 hasConceptScore W1881168102C71924100 @default.
• W1881168102 hasIssue "15_suppl" @default.
• W1881168102 hasLocation W18811681021 @default.
• W1881168102 hasOpenAccess W1881168102 @default.
• W1881168102 hasPrimaryLocation W18811681021 @default.
• W1881168102 hasRelatedWork W1969578744 @default.
• W1881168102 hasRelatedWork W1991412268 @default.
• W1881168102 hasRelatedWork W2005537476 @default.
• W1881168102 hasRelatedWork W2319496893 @default.
• W1881168102 hasRelatedWork W2349340765 @default.
• W1881168102 hasRelatedWork W2365966720 @default.
• W1881168102 hasRelatedWork W2370585970 @default.
• W1881168102 hasRelatedWork W2376347278 @default.
• W1881168102 hasRelatedWork W2419408601 @default.
• W1881168102 hasRelatedWork W3196960728 @default.
• W1881168102 hasVolume "31" @default.

• next